regulatory authorities have a different view [Dissolution / BCS / IVIVC]

posted by Dr_Dan  – Germany, 2015-09-15 10:53 (3479 d 04:05 ago) – Posting: # 15398
Views: 10,676

Dear Mauricio
in contrast to stable drugs the curve of the dissolution profile of a capecetabine formulation will not asymptotically approximate the 100% but decline after reaching a maximum which can not be 100%. It is reasonable to assume that everything is all right as Long as you can show similarity of the disso profile of your test formulation with the reference formulation, however, you have no proof. IMHO this is the reason why regulatory authorities have a different view (see this recent post of Helmut). In disso testing you regard two processes, disintegration and dissolution. In case of capecitabine there is a third process, degradation. It could be assumed that this third processes superimposes the first two processes and that therefore differences in formulation can not be detected.
I hope this helps.
Kind regards
Dr_Dan

Kind regards and have a nice day
Dr_Dan

Complete thread:

UA Flag
Activity
 Admin contact
23,409 posts in 4,921 threads, 1,711 registered users;
29 visitors (0 registered, 29 guests [including 6 identified bots]).
Forum time: 13:59 CET (Europe/Vienna)

It’s easy to lie with statistics;
it is easier to lie without them.    Frederick Mosteller

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5